Study shows MS drugs are cost effective
The six year data from the ten year Risk-sharing Scheme project has found that the beta interferon drugs and glatiramer acetate are cost effective treatments for the NHS. People taking one of these drugs showed a slower increase in EDSS measures than predicted for untreated controls.
Pharmaceutical Journal
Risk-sharing Scheme
Source: Multiple Sclerosis Trust - Category: Neurology Source Type: news